Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1421 studies found for:    gene therapy | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Gene Therapy for X-CGD
Condition: X-linked Chronic Granulomatous Disease
Intervention: Genetic: ex-vivo gene-therapy
2 Not yet recruiting Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Surgery combined with rAd-p53 gene therapy;   Procedure: Surgery
3 Unknown  rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors
Condition: Advanced Malignant Thyroid Tumors
Interventions: Drug: rAd-p53 gene;   Procedure: surgery;   Drug: p53 gene therapy;   Radiation: p53 gene therapy with radioactive iodine
4 Unknown  rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors
Condition: Advanced Oral and Maxillofacial Malignant Tumors
Interventions: Drug: p53 gene with surgery;   Procedure: surgery;   Drug: p53 with chemotherapy;   Drug: p53 gene therapy
5 Recruiting Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
Conditions: Severe Combined Immunodeficiency;   Malignancy, Hematologic;   Neuroblastoma;   Neoplasm;   Mucopolysaccharidosis I
Intervention: Procedure: Venipuncture
6 Not yet recruiting Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease
Condition: Granulomatous Disease, Chronic, X-linked
Intervention: Biological: Lentiviral G1XCGD Gene Therapy
7 Recruiting EndocardialVascularEndothelialGrowth Factor D(VEGF-D)Gene Therapy for the Treatment of Severe Coronary Heart Disease
Conditions: Angina Pectoris;   Myocardial Infarction
Intervention: Biological: VEGF-D gene transfer
8 Recruiting Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B
Condition: Hemophilia B
Intervention: Biological: AskBio009
9 Recruiting Gene Therapy for Wiskott-Aldrich Syndrome
Condition: Wiskott-Aldrich Syndrome
Intervention: Genetic: Autologous CD34 positive cells transduced with WAS encoding lentiviral vector.
10 Recruiting Gene Therapy ADA Deficiency
Condition: Adenosine Deaminase Deficiency
Intervention: Biological: Intravenous infusion of transduced cells
11 Recruiting WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
Conditions: Acute Myeloid Leukaemia;   Chronic Myeloid Leukaemia
Intervention: Genetic: WT1 TCR-transduced T cells
12 Recruiting Gene Therapy for WAS
Condition: Wiskott-Aldrich Syndrome
Intervention: Genetic: Autologous CD34 positive cells transduced with WASP lentiviral vector containing human WASP gene
13 Recruiting Gene Therapy for Wiskott-Aldrich Syndrome (WAS)
Condition: Wiskott-Aldrich Syndrome
Intervention: Genetic: Autologous CD34 positive cells transduced with WASP lentiviral vector containing human WASP gene
14 Unknown  Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients
Condition: HIV Infections
Interventions: Genetic: GX-12;   Drug: HAART
15 Unknown  Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)
Condition: X-linked Severe Combined Immunodeficiency
Intervention: Genetic: Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
16 Not yet recruiting Gene Therapy for Netherton Syndrome
Condition: Netherton Syndrome
Intervention: Genetic: One 20cm2/10cm2 autologous skin sheet graft
17 Recruiting Gene Therapy for Metachromatic Leukodystrophy
Condition: Metachromatic Leukodystrophy
Intervention: Genetic: Autologous CD34+ stem cells transduced with ARSA encoding lentiviral vector
18 Unknown  p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage
Condition: Neoplasms
Interventions: Drug: chemotherapy plus p53;   Drug: chemotherapy;   Radiation: radiotherapy
19 Not yet recruiting An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia
Condition: Choroideremia
Intervention: Genetic: rAAV2.REP1 vector
20 Recruiting Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation
Conditions: Leber's Hereditary Optic Neuropathy;   G11778A Gene Mutation;   Human Mitochondrial ND4 Gene
Interventions: Drug: scAAV2-P1ND4v2 5.00x10e9 vg (Low),;   Drug: scAAV2-P1ND4v2 2.46X10e10 vg (Med);   Drug: scAAV2-P1ND4v2 1.0X10e11vg (High)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years